Half of Medicare's Mismatched Drug Codes Are Saline
OIG spent fourteen months inside one year of Part B drug claims and came back with 160,918 lines where the HCPCS code does not match the NDC sitting beside it. Three saline codes are half of them, nothing in the claims system edits for it, and the brief closes with no recommendations. Also in the window: the fee schedule's statutory deadline runs out today with the OMB tracker returning 502 on every path, and Cigna quietly moved its entire coverage policy library to a new domain.
OIG spent fourteen months inside a single year of Medicare Part B drug claims.
10,527,895 outpatient claim lines, every one of them carrying both a HCPCS code and an NDC, and $17,275,445,011 paid against them.
It came back with 160,918 lines where the two do not agree.
More than half of those are saline.
"What happens to a national billing pattern that nothing in the claims system is built to catch?"
Three Saline Codes Carry Half of It
The document is OAS-25-09-090, issued October 23 and posted Wednesday. It is labelled a data brief rather than an audit, and that distinction matters.
The 160,918 lines were billed by 2,944 providers using 577 distinct HCPCS codes that do not map to the NDC on the same line, checked against CMS's own Part B drug crosswalk. The volume is steady, 38,512 to 42,994 lines in every quarter of the audit period.
Six of the 577 codes carry 62 percent of it, and the six are not the ones you would pick (chart above).
J7050, J7040 and J7030, the 250 cc, 500 cc and 1,000 cc presentations of normal saline, account for 83,233 lines between them. That is 51.7 percent of the entire national finding.
Rounding out the top six: acetaminophen, cyclophosphamide and cefazolin sodium.
The other 571 codes split 61,653 lines.
The rest of this brief is for subscribers.
The impact tables, the code-level detail, and the rest of the analysis sit past this line.
$50 a month, or $500 a year.
Already a subscriber? Sign in